Thromb Haemost 2008; 99(04): 791-792
DOI: 10.1160/TH07-11-0657
Letters to the Editor
Schattauer GmbH

Thrombin regulation in neonates undergoing cardiopulmonary bypass

Satu Långström
1   Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
,
Paula Rautiainen
2   Department of Anesthesia and Intensive Care, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
,
Leena Mildh
2   Department of Anesthesia and Intensive Care, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
,
Kaija Peltola
2   Department of Anesthesia and Intensive Care, Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
,
Ulla Wartiovaara-Kautto
3   Helsinki University Central Hospital Laboratory Services (HUSLAB), Department of Clinical Chemistry, Laboratory of Hematology, University of Helsinki, Finland
,
Markku Heikinheimo
1   Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
4   Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
,
Jari Petäjä
1   Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
5   Department of Pediatrics, Jorvi Hospital, University of Helsinki, Espoo, Finland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 04. November 2007

Accepted after major revision: 26. Februar 2008

Publikationsdatum:
25. November 2017 (online)

 

 
  • References

  • 1 Chandler WL, Velan T. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass. Blood 2003; 101: 4355-4362.
  • 2 Raivio P, Kuitunen A, Suojaranta-Ylinen R. et al. Thrombin generation during reperfusion after cardiopulmonary bypass predicts postoperative myocardial damage in patients undergoing coronary artery bypass surgery. J Thromb Haemost 2006; 4: 1523-1527.
  • 3 Knudsen L, Hasenkam JM, Kure HH. et al. Monitoring thrombin generation with prothrombin fragment 1.2 assay during cardiopulmonary bypass surgery. Thromb Res 1996; 84: 45-54.
  • 4 Jormalainen M, Vento AE, Wartiovaara-Kautto U. et al. Recombinant hirudin enhances cardiac output and decreases systemic vascular resistance during reperfusion after cardiopulmonary bypass in a porcine model. J Thorac Cardiovasc Surg 2004; 128: 189-196.
  • 5 Långström S, Wartiovaara-Kautto U, Andersson S. et al. Exchange transfusion activates coagulation and alters the coagulation profile in newborn infants. Thromb Haemost 2006; 96: 142-148.
  • 6 Van Beaumont W. Evaluation of hemoconcentration form hematocrit measurements. J Appl Phys 1972; 32: 712-713.
  • 7 Guzzetta NA, Miller BE, Todd K. et al. An evaluation of the effects of a standard heparin dose on thrombin inhibition during cardiopulmonary bypass in neonates. Anesth Analg 2005; 100: 1276-1282.
  • 8 Mössinger H, Dietrich W, Braun SL. et al. Highdose aprotinin reduces activation of hemostasis, allogenic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003; 75: 430-437.
  • 9 Petäjä J, Pesonen E, Fernandez JA. et al. Cardiopulmonary bypass and activation of antithrombotic plasma protein C. J Thorac Cardiovasc Surg 1999; 118: 422-429.
  • 10 Eisses MJ, Velan T, Aldea GS. et al. Strategies to reduce hemostatic activation during cardiopulmonary bypass. Thromb Res 2006; 117: 689-703.
  • 11 Jansen NJ, Van Oereven W, Van Vliet MH. et al. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 744-748.
  • 12 Farivar AS, Delgado MF, McCourtie AS. et al. Crosstalk between thrombosis and inflammation in lung reperfusion injury. Ann Thorac Surg 2006; 81: 1061-1067.
  • 13 Flaujac C, Pouard P, Boutouyrie P. et al. Platelet dysfunction after normothermic cardiopulmonary bypass in children: Effect of high-dose aprotinin. Thromb Haemost 2007; 98: 385-391.